文献速递肾小球疾病

特发性膜性肾病中PLA2R表位图谱及其临床意义

Mapping of Phospholipase A2 Receptor Epitopes in Idiopathic Membranous Nephropathy and Clinical Relevance of Epitope Profiles.
PubMed 文献 · J Am Soc Nephrol · 2025-12-08

本研究基于酵母表面展示技术构建PLA2R抗原库,在389例特发性膜性肾病患者中鉴定出CTLD4、CTLD5和CTLD6三个新抗原表位,并发现表位数量与肾病综合征风险及临床缓解相关。

要点

  • 新发现PLA2R的CTLD4、CTLD5、CTLD6三个抗原表位。
  • 每增加一个表位,肾病综合征风险增加56%(OR 1.56)。
  • 每增加一个表位,临床缓解可能性降低15%(HR 0.85)。

核心结论

  • PLA2R表位图谱与膜性肾病的疾病严重程度和预后相关。

研究设计与样本

  • 基于酵母表面展示系统构建PLA2R抗原库,纳入389例特发性膜性肾病患者。

主要发现

  • 320例(82%)患者显示Ricin结构域以外的表位。
  • CTLD1、CTLD5、CTLD7阳性率分别为53%、45%、54%,CTLD6、CTLD8、CTLD4分别为9%、8%、7%。
  • 多变量模型显示每增加一个表位肾病综合征风险增加56%(OR 1.56,95%CI 1.28-1.91)。
  • 多变量Cox回归显示每增加一个表位临床缓解可能性降低15%(HR 0.85,95%CI 0.75-0.96)。
  • 中介分析显示抗PLA2R滴度解释该效应的12%。

关键数值与推荐

  • 每增加一个表位肾病综合征风险OR 1.56(95%CI 1.28-1.91)。
  • 每增加一个表位临床缓解HR 0.85(95%CI 0.75-0.96)。
  • 抗PLA2R滴度中介效应占12%。

临床怎么用

  • 检测PLA2R表位谱可能有助于评估膜性肾病疾病严重程度和预后。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

KEY POINTS: Based on the yeast surface display system, we identified three new antigen epitopes of CTLD4, CTLD5, and CTLD6 of phospholipase A2 receptor in membranous nephropathy. In the cohort, 82% of patients showed epitopes beyond Ricin and 56% higher risk for nephrotic syndrome per one more epitope (odds ratio, 1.56; 95% confidence interval, 1.28 to 1.91). Each additional epitope was associated with 15% lower likelihood in clinical remission in this membranous nephropathy cohort (hazard ratio, 0.85; 95% confidence interval, 0.75 to 0.96). BACKGROUND: The M-type phospholipase A2 receptor (PLA2R) is the main target antigen of idiopathic membranous nephropathy. Four autoantibody-targeted PLA2R epitope domains, including Ricin, CTLD1, CTLD7, and CTLD8, have been identified. Nevertheless, whether the epitope profile is involved in the progression of PLA2R-associated membranous nephropathy remains controversial. Conventional epitope detection techniques have limitations, and new methods are needed. METHODS: We constructed a yeast surface-displayed PLA2R antigen library by randomly fragmenting the full-length PLA2R gene and expressing them on the yeast surfaces. Fluorescence-activated cell sorting was performed with sera from PLA2R-related membranous nephropathy patients. Antigenic epitopes were identified through sequencing and clustering. To analyze large-scale samples in batches, we used representative monoclonal yeasts of each structural domain, obtained through the sorting procedure for flow analysis. Clinical and laboratory data were collected at baseline and follow-up. Associations between epitope numbers and disease conditions and prognosis were analyzed. RESULTS: The capacity, diversity, and screening specificity of the PLA2R yeast surface display library were validated. Beyond the reported epitopes, CTLD4, CTLD5, and CTLD6 were newly identified as antigenic targets. In our cohort of 389 idiopathic membranous nephropathy patients, 320 (82%) patients showed epitopes beyond the Ricin domain. The positive rates of CTLD1, CTLD5, and CTLD7 were 53%, 45%, and 54%, respectively, while the detection rates of CTLD6, CTLD8, and CTLD4 were lower at 9%, 8%, and 7%, respectively. The multivariable model demonstrated a 56% higher risk for nephrotic syndrome per epitope increment (odds ratio, 1.56; 95% confidence interval, 1.28 to 1.91) after adjustment for gender, age, disease duration, serum creatinine, and anti-PLA2R titer. Multivariable Cox regression demonstrated that each additional epitope was associated with a 15% lower likelihood in clinical remission (hazard ratio, 0.85; 95% confidence interval, 0.75 to 0.96), with subsequent mediation analysis revealing anti-PLA2R titer accounted for 12% of this effect. CONCLUSIONS: Based on the PLA2R yeast surface display system, we identified three new antigen epitopes of PLA2R in membranous nephropathy. The epitope profiles of PLA2R were associated with disease severity and prognosis of membranous nephropathy.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Liu Y, Chen P, Chen G, et al. Mapping of Phospholipase A2 Receptor Epitopes in Idiopathic Membranous Nephropathy and Clinical Relevance of Epitope Profiles. J Am Soc Nephrol. 2025. PMID: 41563797. doi:10.1681/ASN.0000000962

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。